Baker Bros. Advisors’s Prelude Therapeutics PRLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.19M | Hold |
10,123,824
| – | – | 0.08% | 56 |
|
|
2025
Q1 | $7.78M | Hold |
10,123,824
| – | – | 0.09% | 49 |
|
|
2024
Q4 | $12.9M | Hold |
10,123,824
| – | – | 0.14% | 48 |
|
|
2024
Q3 | $21M | Hold |
10,123,824
| – | – | 0.22% | 41 |
|
|
2024
Q2 | $38.6M | Hold |
10,123,824
| – | – | 0.49% | 28 |
|
|
2024
Q1 | $48M | Hold |
10,123,824
| – | – | 0.6% | 27 |
|
|
2023
Q4 | $43.2M | Hold |
10,123,824
| – | – | 0.49% | 25 |
|
|
2023
Q3 | $31.3M | Hold |
10,123,824
| – | – | 0.18% | 25 |
|
|
2023
Q2 | $45.6M | Hold |
10,123,824
| – | – | 0.26% | 26 |
|
|
2023
Q1 | $57.7M | Hold |
10,123,824
| – | – | 0.31% | 20 |
|
|
2022
Q4 | $61.1M | Hold |
10,123,824
| – | – | 0.37% | 21 |
|
|
2022
Q3 | $66.9M | Hold |
10,123,824
| – | – | 0.44% | 22 |
|
|
2022
Q2 | $52.8M | Hold |
10,123,824
| – | – | 0.3% | 23 |
|
|
2022
Q1 | $69.9M | Hold |
10,123,824
| – | – | 0.4% | 22 |
|
|
2021
Q4 | $126M | Hold |
10,123,824
| – | – | 0.61% | 15 |
|
|
2021
Q3 | $316M | Hold |
10,123,824
| – | – | 1.39% | 9 |
|
|
2021
Q2 | $290M | Hold |
10,123,824
| – | – | 1.27% | 10 |
|
|
2021
Q1 | $439M | Buy |
10,123,824
+5,188
| +0.1% | +$225K | 1.9% | 10 |
|
|
2020
Q4 | $724M | Hold |
10,118,636
| – | – | 2.73% | 7 |
|
|
2020
Q3 | $305M | Buy |
+10,118,636
| New | +$305M | 1.22% | 11 |
|